Med. praxi. 2011;8(4):156-159

Current treatment of essential arterial hypertension

MUDr.Filip Málek, Ph.D., MBA
Kardiovaskulární centrum, Nemocnice Na Homolce, 3. LF UK, Praha

The efficacy of antihypertensive therapy on cardiovascular mortality and morbidity is based on the effect on blood pressure lowering.

Effective decrease of blood pressure is provided by: thiazide diuretics, beta-blockers, calcium channel blockers, angiotensin-converting

enzyme inhibitors and angiotensin receptor blockers. These drugs represent the treatment of choice either for monotherapy, or for the

combination. Pharmacotherapy of hypertension is guided either by blood pressure level, the presence of associated clinical condition, the

severity of target organ damage and the total cardiovascular risk. Up-to now, there is no evidence of the treatment benefit in the management

of high normal blood pressure. The choice of the treatment drug group depends on the type of the associated clinical condition.

hypertension crisis.

Keywords: arterial hypertension, pharmacotherapy, guidelines, target values, cardiovascular risk, combination therapy, resistant hypertension,

Published: May 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Málek F. Current treatment of essential arterial hypertension. Med. praxi. 2011;8(4):156-159.
Download citation

References

  1. Vasan R, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of frequency of progression to hypertension in nonhypertensive participants in the Framingham Heart Study: a cohort study. Lancet 2001; 358: 1682-1686. Go to original source... Go to PubMed...
  2. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth joint task force of the european society of cardiology and other societies on cardiovasclar disease prevention in clinical practice. Eur Heart J 2007; 28: 2375-2414.
  3. 2007 Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). Journal of Hypertension 2007; 25: 1105-1187. Go to PubMed...
  4. Widimský J, Cífková R, Špinar K, et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2007 Cor Vasa 2008; 50(1): Kardio K3-K16.
  5. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension managemenent: a European society of hypertension task force document. Journal of Hypertension, 2009; 27(11): 2121-2158. Go to original source... Go to PubMed...
  6. Widimský J Jr. Komentář k přehodnocení evropských doporučení léčby arteriální hypertenze. Cor Vasa 2010; 52(1-2): 75-78. Go to original source...
  7. Špinar J, Souček M. Přehodnocení doporučení pro diagnostiku a léčbu hypertenze. Vnitř Lék 2010; 56(2): 157-161. Go to PubMed...
  8. Conroy R, Pyörälä K, Fitzgerald AP, et al. SCORE project group. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003. Go to original source... Go to PubMed...
  9. Widimský J jr, Widimský J. Rezistentní hypertenze. In: Hypertenze. 3. rozšířené a přepracované vydání. Triton, 2008: 427-435.
  10. Alderman MH, Budner N, Cohen H, et al. Prevalence of drug resistant hypertension. Hypertension 1988; 11(Suppl II): II71-II75. Go to original source... Go to PubMed...
  11. Beckett R, Peters AE, Fletcher, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008: 358. Go to original source... Go to PubMed...
  12. Pepine CJ, Handberg EM, Coper-DeHorf RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The international Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805-8816. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.